Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQLNASDAQ:EXASNASDAQ:HALONASDAQ:NBIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQLArQule$20.00$20.00$3.15▼$20.45$2.42B2.495.27 million shsN/AEXASExact Sciences$53.02+1.3%$51.87$39.97▼$72.83$10.00B0.982.57 million shs3.80 million shsHALOHalozyme Therapeutics$52.81-0.6%$56.73$42.01▼$70.51$6.51B1.191.65 million shs5.66 million shsNBIXNeurocrine Biosciences$126.55-0.6%$116.55$84.23▼$157.98$12.52B0.241.14 million shs1.58 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQLArQule0.00%0.00%0.00%0.00%0.00%EXASExact Sciences+1.30%-0.93%-6.80%+16.22%+26.48%HALOHalozyme Therapeutics-0.64%-2.17%-2.08%-18.95%+5.05%NBIXNeurocrine Biosciences-0.60%+1.74%+4.97%+13.07%-3.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQLArQuleN/AN/AN/AN/AN/AN/AN/AN/AEXASExact Sciences4.6816 of 5 stars4.53.00.04.72.32.50.6HALOHalozyme Therapeutics4.8705 of 5 stars3.12.00.04.42.92.54.4NBIXNeurocrine Biosciences4.7565 of 5 stars4.43.00.02.92.62.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQLArQule 0.00N/AN/AN/AEXASExact Sciences 2.95Moderate Buy$70.9033.72% UpsideHALOHalozyme Therapeutics 2.17Hold$61.9017.21% UpsideNBIXNeurocrine Biosciences 2.86Moderate Buy$162.0028.01% UpsideCurrent Analyst Ratings BreakdownLatest ARQL, NBIX, EXAS, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025NBIXNeurocrine BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$145.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/14/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.005/13/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/13/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$47.005/7/2025HALOHalozyme TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2025HALOHalozyme TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.005/6/2025NBIXNeurocrine BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/6/2025NBIXNeurocrine BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.005/6/2025NBIXNeurocrine BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.005/6/2025NBIXNeurocrine BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$137.00 ➝ $152.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQLArQule$25.76M93.85N/AN/A$0.72 per share27.78EXASExact Sciences$2.76B3.63$5.63 per share9.42$12.98 per share4.08HALOHalozyme Therapeutics$1.02B6.41$4.65 per share11.35$2.86 per share18.47NBIXNeurocrine Biosciences$2.36B5.32$3.38 per share37.44$25.58 per share4.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQLArQule-$15.48M-$0.16N/AN/AN/A-805.61%-33.10%-26.87%N/AEXASExact Sciences-$1.03B-$5.51N/A106.0440.25-36.06%-3.75%-1.68%7/30/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$3.7614.058.490.3544.76%136.91%26.05%8/5/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$2.9542.9019.561.3012.68%11.81%8.59%7/30/2025 (Estimated)Latest ARQL, NBIX, EXAS, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million5/5/2025Q1 2025NBIXNeurocrine Biosciences$0.70$0.08-$0.62$0.08$587.06 million$572.60 million5/1/2025Q1 2025EXASExact Sciences-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQLArQuleN/AN/AN/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQLArQule0.088.278.27EXASExact Sciences0.972.732.38HALOHalozyme Therapeutics3.138.397.30NBIXNeurocrine BiosciencesN/A3.133.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQLArQule74.63%EXASExact Sciences88.82%HALOHalozyme Therapeutics97.79%NBIXNeurocrine Biosciences92.59%Insider OwnershipCompanyInsider OwnershipARQLArQule13.80%EXASExact Sciences1.20%HALOHalozyme Therapeutics2.40%NBIXNeurocrine Biosciences4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQLArQule36120.87 millionN/AOptionableEXASExact Sciences7,000188.64 million186.37 millionOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableNBIXNeurocrine Biosciences1,80098.97 million94.22 millionOptionableARQL, NBIX, EXAS, and HALO HeadlinesRecent News About These CompaniesNeurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive DyskinesiaJune 20 at 8:30 AM | prnewswire.comSowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 20 at 4:03 AM | marketbeat.comPallas Capital Advisors LLC Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 14, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 14, 2025 | marketbeat.comNeurocrine Biosciences' SWOT analysis: biotech stock balances Ingrezza success with pipeline potentialJune 14, 2025 | investing.comStanley Laman Group Ltd. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 13, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by TobamJune 13, 2025 | marketbeat.comAssenagon Asset Management S.A. Buys 367,315 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 13, 2025 | marketbeat.comHandelsbanken Fonder AB Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 13, 2025 | marketbeat.comDavis Investment Partners LLC Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 12, 2025 | marketbeat.comCantor Fitzgerald Weighs in on NBIX FY2026 EarningsJune 12, 2025 | americanbankingnews.comSG Americas Securities LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 11, 2025 | marketbeat.comNeurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Lewis Choi as Chief Information OfficerJune 10, 2025 | finanznachrichten.deAnalysts Issue Forecasts for NBIX FY2026 EarningsJune 10, 2025 | marketbeat.comCongress Asset Management Co. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 10, 2025 | marketbeat.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX stock newsJune 9, 2025 | gurufocus.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX Stock NewsJune 9, 2025 | gurufocus.comNeurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock NewsJune 9, 2025 | gurufocus.comNeurocrine Biosciences names new Chief Information OfficerJune 9, 2025 | investing.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information OfficerJune 9, 2025 | prnewswire.comNxera Pharma earns $15m payment as first patient in schizophrenia drug trial is dosed by Neurocrine BiosciencesJune 6, 2025 | cambridgeindependent.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARQL, NBIX, EXAS, and HALO Company DescriptionsArQule NASDAQ:ARQLArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.Exact Sciences NASDAQ:EXAS$53.02 +0.68 (+1.30%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$52.89 -0.13 (-0.25%) As of 06/20/2025 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Halozyme Therapeutics NASDAQ:HALO$52.81 -0.34 (-0.64%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$52.83 +0.02 (+0.04%) As of 06/20/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Neurocrine Biosciences NASDAQ:NBIX$126.55 -0.76 (-0.60%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$127.32 +0.77 (+0.61%) As of 06/20/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
